Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00116298 | Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) | PHASE3 | COMPLETED | 900 | — | — | Jan 1, 2001 | Jan 1, 2005 | Apr 25, 2011 | 63 | United States, Argentina +14 |
| NCT00000789 | A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection | PHASE2 | COMPLETED | 230 | — | — | - | Jul 1, 1998 | Nov 4, 2021 | 54 | United States, Puerto Rico |
| Name | Type | Description |
|---|---|---|
| stavudine, efavirenz, lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria: * Completed d4T studies AI455-096 or AI455-099 * Have demonstrated compliance with the study medication and treatment visits * Provide written informed consent * Agree to use a barrier method of birth control (such as condoms) during the study * Have a negative pregnancy test wi...